BCLI stock forecast
Our latest prediction for Brainstorm Cell Therapeutics, Inc.'s stock price was made on the Dec. 24, 2019 when the stock price was at 3.95$.
In the short term (2weeks), BCLI's stock price should underperform the market by -0.94%. During that period the price should oscillate between -9.24% and +11.27%.
In the medium term (3months), BCLI's stock price should underperform the market by -7.52%. During that period the price should oscillate between -41.27% and +26.11%.Get email alerts
Create a solid portfolio with BCLI
About Brainstorm Cell Therapeutics, Inc.
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.13$ per share.
The book value per share is 0.62$
Three months stock forecastDec. 24, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|